The market situation for 2-FA, a synthetic designer drug categorized as a research chemical, has evolved significantly in recent years. 2-FA, short for 2-Fluoroamphetamine, has gained attention within the online vendor community, making it readily available.
Numerous sellers offer 2-FA online, catering to researchers and individuals seeking novel compounds for experimentation. Its status as a research chemical allows vendors to market it without explicitly promoting human consumption, helping it circumvent certain legal restrictions.
Buyers, primarily comprising research institutions and scientists, are drawn to 2-FA due to its potential for unique pharmacological effects. Researchers are eager to explore its properties, often leading to increased demand in the market.
However, the legal status of 2-FA remains to be determined in many jurisdictions, leading to a complex and ever-evolving regulatory landscape. This ambiguity prompts caution among sellers and buyers, as legal consequences may vary depending on location.
- 1 Summary
- 2 Chemistry
- 3 Pharmacology
- 4 Subjective effects
- 5 Toxicity
- 6 Legal status
- 7 FAQ
- 7.1 1. What is 2-FA?
- 7.2 2. How does 2-FA work?
- 7.3 3. Is 2FA legal?
- 7.4 4. What are the expected effects of 2-FA?
- 7.5 5. Is 2-FA safe to use?
- 7.6 6. What are the potential risks of using 2-FA?
- 7.7 7. Can 2-FA be detected in drug tests?
- 7.8 8. How is 2-FA typically consumed?
- 7.9 9. Is 2-FA used for any medical purposes?
- 8 References
2-Fluoroamphetamine, or 2-FA, is an innovative stimulant within the amphetamine class. It shares a structural resemblance to amphetamine and is presumed to operate through a similar mechanism, facilitating the brain’s release of dopamine and norepinephrine.
2-FA belongs to a series of amphetamine analogues that emerged in the online research chemical market during the 2010s. This group includes compounds such as 2-FMA, 3-FA, 3-FEA, and 4-FA, all known for producing various stimulating and euphoric effects. Many have been explored as research chemical substitutes for traditional street stimulants and entactogens. Among these analogues, 2-FA is renowned for its likeness to d-amphetamine (Dexedrine) in terms of subjective effects.
Typically, 2-FA is administered orally, as alternative methods like insufflation or vaporization have been reported as highly discomforting and unpleasant compared to its parent compound. While some users have suggested its potential as an alternative to prescription stimulants for conditions like ADHD, limited knowledge exists regarding its potential long-term toxicological effects when used as a substitute for prescribed stimulants.
The understanding of 2-FA’s pharmacological properties, metabolism, and toxicity remains underexplored, mainly emphasizing the importance of harm reduction practices for individuals considering its use. Given the absence of data, caution is paramount when engaging with this substance.
2-Fluoroamphetamine, known as 2-FA, is a synthetic compound belonging to the amphetamine family. Amphetamine-class molecules share a phenethylamine core characterized by a phenyl ring linked to an amino (NH2) group through an ethyl chain. Additionally, they feature a methyl substitution at Rα. This structural feature classifies amphetamines as alpha-methylated phenethylamines.
In contrast to its close relative, 2-FMA, 2-FA lacks a methyl group attached to the terminal amine RN of the amphetamine core. This structural distinction renders 2-FA similar in both structure and function to amphetamine itself. Essentially, 2-FA represents the fluorinated analogue of amphetamine, with the fluorine atom at the 2-position.
While formal research on 2-FA has not reached the same depth as traditional amphetamines, it is reasonable to surmise that, much like other substituted amphetamines with similar structural substitutions (with the notable exception of 4-FA), its primary mode of action likely involves functioning as both a dopamine and norepinephrine releasing agent. In practical terms, this entails its capacity to enhance the levels of these neurotransmitters in the brain. It accomplishes this by binding to and partially obstructing the transporter proteins responsible for clearing these monoamines from the synaptic cleft.
This process allows for the accumulation of dopamine and norepinephrine within the brain, elevating their levels beyond the usual endogenous range. Consequently, this leads to a spectrum of effects characterized by stimulation, motivation, and euphoria.
In contrast to other substituted amphetamines, 2-FA is known for its relatively mild side effect profile. Users commonly report a lack of adverse effects such as nausea, high blood pressure, anxiety, or an uncomfortable comedown. It is regarded as a functional and efficient psychoactive substance, particularly for tasks requiring productivity, akin to dextroamphetamine.
However, 2-FA is said to transition from a productivity-enhancing agent to a recreational one at higher doses. This shift is characterized by distracting euphoria and heightened stimulation. It’s often noted for having a “ceiling dose,” purportedly lowering the abuse threshold compared to methamphetamine, though this has yet to be scientifically substantiated.
Disclaimer: The effects listed below are based on the Subjective Effect Index (SEI), drawing from anecdotal user reports and the insights of PsychonautWiki contributors. As such, they should be approached with a degree of scepticism. Additionally, the occurrence and intensity of these effects may be somewhat predictable, and higher doses are more likely to encompass the full spectrum of products. It’s crucial to know that elevated amounts can escalate the risk of adverse outcomes, including addiction, severe health complications, or even fatality.
- Physical euphoria
- Pupil dilation
- Enhanced stamina
- Appetite suppression
- Abnormal heartbeat
- Gastrointestinal effects (constipation or diarrhoea)
- Urinary difficulties (difficulty urinating and frequent urination)
- Elevated heart rate
- Increased perspiration
- Elevated blood pressure
- Muscular effects (contractions, cramps, spasms)
- Seizures (rare)
- Stomach cramps
- Temporary erectile dysfunction
- Suppression of temperature regulation
- Teeth grinding
- Tactile effects, including tactile enhancement and hallucinations
- Subtle cognitive effects at low to moderate dosages, similar in strength to caffeine, unlike amphetamine or 2-FMA
- Analysis enhancement
- Anxiety or anxiety suppression
- Cognitive euphoria
- Compulsive redosing
- Ego inflation
- Emotion suppression
- Enhanced focus
- Increased libido
- Heightened music appreciation
- Motivation enhancement
- Thought acceleration
- Thought organization or disorganization
- Time distortion, often experienced as an accelerated perception of time
The post-stimulant experience, often called the “comedown,” is generally less enjoyable than the peak effects and is attributed to neurotransmitter depletion. Common aftereffects include:
- Cognitive fatigue
- Feelings of impending doom
- Motivation suppression
- Thought deceleration
- Prolonged wakefulness
It’s essential to exercise caution and adhere to responsible dosing practices to mitigate potential adverse effects when using 2-FA.
The toxicity and long-term health implications of recreational 2-FA use still need to be more adequately studied within a scientific context, resulting in an unknown exact toxic dosage. This lack of comprehensive research is primarily due to humans’ limited historical usage of 2-FA. Anecdotal feedback from individuals within the community who have experimented with 2-FA suggests that there haven’t been significant adverse health effects associated with trying this substance at low to moderate doses when used sparingly. However, it’s important to emphasize that no guarantees can be made regarding individual reactions.
In the realm of medicinal chemistry, the introduction of a fluorine substitution is occasionally considered advantageous in central nervous system pharmaceutical agents. This practice is expected due to the corresponding increase in lipophilicity granted by the fluorine substitution.
Harm reduction practices are strongly recommended when using this substance.
Tolerance and addiction potential:
Chronic use of 2-FA is comparable to other stimulants in terms of moderate addiction potential and a propensity for abuse. It can lead to psychological dependence in certain users. The development of dependence or addiction may result in cravings and withdrawal symptoms if usage is abruptly ceased.
Tolerance to many of 2-FA’s effects tends to develop with prolonged and repeated use. Users must consume progressively larger doses to achieve the same impact over time. It takes approximately 3 – 7 days for the tolerance to decrease by half and 1 – 10 days to return to baseline without further consumption. Furthermore, 2-FA exhibits cross-tolerance with all dopaminergic stimulants. This implies that after using 2-FA, all stimuli will have a reduced effect, including unexpected ones such as MDMA, which relies on dopamine and norepinephrine for its full euphoric effect.
Abuse of substances in the amphetamine class at high doses and over prolonged durations can potentially induce stimulant psychosis, characterized by symptoms like paranoia, hallucinations, and delusions. Treatment for amphetamine-induced psychosis may be required in some cases.
Combining 2-FA with certain other substances can be hazardous, potentially resulting in life-threatening situations. Caution is advised, and independent research should always be conducted to ensure the safety of such combinations. Some known dangerous interactions include alcohol, GHB/GBL, opioids, cocaine, cannabis, caffeine, tramadol, DXM, ketamine, PCP, methoxetamine, psychedelics (e.g., LSD, mescaline, psilocybin), 25x-NBOMe, 2C-T-x, 5-MeO-xxT, DOx, aMT, and MAOIs. These interactions can lead to various adverse effects, including cardiovascular complications, mental health issues, and other serious medical concerns.
2-FA currently falls into a legal grey area worldwide, which means its regulatory status is ambiguous, and it is not explicitly classified as illegal (“scheduled”) in any country’s legislation. However, it’s important to note that possession charges may still be levied under specific circumstances, such as analogue laws or with intent to sell or consume.
Here is the regulatory status of 2-FA in various countries:
- Canada: In Canada, 2-FA would typically be categorized as a Schedule I substance due to its status as an amphetamine analogue.
- China: As of October 2015, 2-FA is classified as a controlled substance in China.
- Germany: Germany controls 2-FA under the NpSG (New Psychoactive Substances Act) since November 26, 2016. This includes penalties for production, import to market, administration to others, and trading. Possession is illegal but not penalized.
- New Zealand: In New Zealand, 2-FA is considered an amphetamine analogue and is listed as a Schedule 3 controlled substance.
- Switzerland: 2-FA is explicitly named and controlled under Verzeichnis E in Switzerland. It is legal for scientific or industrial use but restricted otherwise.
- Turkey: Turkey classifies 2-FA as a drug and strictly prohibits its possession, production, supply, or import.
- United Kingdom: 2-FA is categorized as a Class A drug in the United Kingdom, primarily due to its status as an amphetamine analogue under the Misuse of Drugs Act 1971.
- United States: In the United States, 2-FA may be considered an analogue of amphetamine under the Federal Analogue Act. This could potentially classify it as a Schedule II drug. The Federal Analogue Act treats chemicals as if they were in Schedule I or II if they are substantially similar to illegal drugs and intended for human consumption.
Please note that legal interpretations and regulations may change over time, and verifying the current legal status of 2-FA in your specific jurisdiction is crucial.
1. What is 2-FA?
- 2-FA, or 2-Fluoroamphetamine, is a synthetic compound in the amphetamine class of stimulants. It is a structural analogue of amphetamine, with a fluorine atom added to the molecule.
2. How does 2-FA work?
- 2-FA is believed to work by increasing neurotransmitters in the brain, including dopamine and norepinephrine. It does this by binding to and partially blocking transporter proteins responsible for clearing these neurotransmitters from the synaptic cleft.
3. Is 2FA legal?
- The legal status of 2-FA varies by country. It is considered a controlled substance in some nations, while in others, it falls into a legal grey area. It’s crucial to check the specific regulations in your region.
4. What are the expected effects of 2-FA?
- 2-FA is reported to produce stimulating, motivating, and euphoric effects. Users often describe increased energy, focus, and alertness. It may also lead to physical products like increased heart rate and appetite suppression.
5. Is 2-FA safe to use?
- The safety of 2-FA is not well-documented, and its long-term effects are largely unknown. As with any psychoactive substance, risks include potential addiction, tolerance, and adverse reactions. Using harm reduction practices is strongly recommended.
6. What are the potential risks of using 2-FA?
- Some potential risks associated with 2-FA use include addiction, psychological dependence, anxiety, paranoia, and physical side effects such as increased heart rate and dehydration. The long-term health effects are uncertain due to limited research.
7. Can 2-FA be detected in drug tests?
- 2-FA may not be detected in standard drug tests, as it is not typically included in routine screenings. However, specialized tests could identify its presence.
8. How is 2-FA typically consumed?
- 2-FA is commonly taken orally. While it can be insufflated or vaporized, these methods are often reported as unpleasant and less effective.
9. Is 2-FA used for any medical purposes?
- 2-FA is not approved for medical use and is primarily encountered in the context of research chemicals and designer drugs.
- Rösner, P., Quednow, B., Girreser, U., Junge, T. (10 March 2005). “Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs)”. Forensic Science International. 148 (2–3): 143–156. doi:10.1016/j.forsciint.2004.05.003.
- Camilleri, A., Johnston, M. R., Brennan, M., Davis, S., Caldicott, D. G. E. (15 April 2010). “Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone”. Forensic Science International. 197 (1–3): 59–66. doi:10.1016/j.forsciint.2009.12.048.
- Smart, B. E. (1 June 2001). “Fluorine substituent effects (on bioactivity)”. Journal of Fluorine Chemistry. 109 (1): 3–11. doi:10.1016/S0022-1139(01)00375-X.
- Shoptaw, S. J., Kao, U., Ling, W. (21 January 2009). Cochrane Drugs and Alcohol Group, ed. “Treatment for amphetamine psychosis”. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003026.pub3.
- Hofmann, F. G. (1983). A handbook on drug and alcohol abuse: the biomedical aspects (2nd ed ed.). Oxford University Press. ISBN 9780195030563.
- [Link] http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf.
- Greenwald, M. K., Lundahl, L. H., Steinmiller, C. L. (December 2010). “Sustained Release d-Amphetamine Reduces Cocaine but not ‘Speedball’-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers”. Neuropsychopharmacology. 35 (13): 2624–2637. doi:10.1038/npp.2010.175.
- Siciliano, C. A., Saha, K., Calipari, E. S., Fordahl, S. C., Chen, R., Khoshbouei, H., Jones, S. R. (10 January 2018). “Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation”. The Journal of Neuroscience. 38 (2): 484–497. doi:10.1523/JNEUROSCI.2604-17.2017.
- Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., D’Souza, D. C. (1 September 2005). “Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function”. Archives of General Psychiatry. 62 (9): 985. doi:10.1001/archpsyc.62.9.985.
- Branch, L. S. (2022), Consolidated federal laws of Canada, Controlled Drugs and Substances Act.
- “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- “Anlage NpSG” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019.
- “Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe” (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 19, 2019.
- “§ 4 NpSG” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019.
- Misuse of Drugs Act 1975 No 116 (as at 01 July 2022), Public Act – New Zealand Legislation.
- “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü.
- [Link] https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf.
- Misuse of Drugs Act 1971.